Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.

Abstract

OBJECTIVE:

Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer's disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD).

METHODS:

In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0 mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD.

RESULTS:

Two treatments showed similar safety and primary and secondary outcomes.

CONCLUSIONS:

Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD.

• Authors: C-H Lin, P-K Chen, S-H Wang, H-Y Lane
• Journal: Journal of psychopharmacology (Oxford, England) (J Psychopharmacol) Vol. 33 Issue 8 Pg. 1030-1033 (08 2019) ISSN: 1461-7285 [Electronic] United States
• PMID: 31113277 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Cholinesterase Inhibitors
• Nootropic Agents
• D-Amino-Acid Oxidase
• Sodium Benzoate

Topics

• Aged
• Alzheimer Disease (drug therapy)
• Cholinesterase Inhibitors (therapeutic use)
• Cognition (drug effects)
• D-Amino-Acid Oxidase (therapeutic use)
• Dementia (drug therapy)
• Double-Blind Method
• Female
• Humans
• Male
• Nootropic Agents (therapeutic use)
• Sodium Benzoate (therapeutic use)
• Treatment Outcome